Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study

Cardiology and Therapy
doi 10.1007/s40119-020-00165-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Idarucizumab for Urgent Reversal of Dabigatran for Heart Transplant: A Case Report

American Journal of Hematology
Hematology
2017English

Idarucizumab for the Reversal of Dabigatran in Patients Undergoing Heart Transplantation

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2018English

Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke

Frontiers in Neurology
Neurology
2019English

Successful Intravenous Thrombolysis for Ischemic Stroke After Reversal of Dabigatran Anticoagulation With Idarucizumab: A Case Report

Journal of Medical Case Reports
Medicine
2017English

Treatment of Comorbid Anxiety and Depression With Escitalopram: Results of a Post-Marketing Surveillance Study

Pharmacopsychiatry
MedicinePsychiatryMental HealthPharmacology
2012English

Adverse Clinical Outcomes After Dabigatran Reversal With Idarucizumab to Facilitate Acute Stroke Thrombolysis

Journal of Neurology
Neurology
2017English

Safety and Effectiveness of Istradefylline in Patients With Parkinson’s Disease: Interim Analysis of a Post-Marketing Surveillance Study in Japan

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2018English

Real-World Evidence for the Safety of Ipragliflozin in Elderly Japanese Patients With Type 2 Diabetes Mellitus (STELLA-ELDER): Final Results of a Post-Marketing Surveillance Study

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2016English

Post-Marketing Surveillance

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy